Plain-English translation of NCT03039439 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at MD Anderson Cancer Center are studying tumor tissue and blood samples from people with parathyroid gland tumors—including benign tumors (adenomas), unusual tumors (atypical neoplasms), and cancerous tumors (carcinomas). By analyzing these samples for specific genetic and molecular patterns, the study aims to identify new ways to distinguish between different types of parathyroid tumors and potentially develop better targeted treatments.
Currently, it can be difficult for doctors to tell the difference between benign parathyroid tumors and more serious ones based on appearance alone. This research could help doctors identify better diagnostic markers and understand which genes are involved in parathyroid tumor development, leading to improved treatment options.
You likely qualify if…
You likely don't qualify if…
If you qualify, researchers will use tumor tissue and blood samples that were already collected during your previous surgery or treatment. This is not an active treatment study—no new procedures or visits are required. The samples will be analyzed in the laboratory to identify genetic patterns and biomarkers, and your medical information will be reviewed to understand how different parathyroid tumors behave.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Enrollment target
~310 participants
Started
November 2015
Primary completion
November 2028
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nancy D. Perrier
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.